Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12.
about
Global Dissemination of Carbapenemase-Producing Klebsiella pneumoniae: Epidemiology, Genetic Context, Treatment Options, and Detection MethodsRapid detection of extended-spectrum-β-lactamase-producing enterobacteriaceae from urine samples by use of the ESBL NDP test.Evaluation of clonality and carbapenem resistance mechanisms among Acinetobacter baumannii-Acinetobacter calcoaceticus complex and Enterobacteriaceae isolates collected in European and Mediterranean countries and detection of two novel β-lactamases,Prospective multicenter study of carbapenemase-producing Enterobacteriaceae from 83 hospitals in Spain reveals high in vitro susceptibility to colistin and meropenem.Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment.In Vivo Evolution of Bacterial Resistance in Two Cases of Enterobacter aerogenes Infections during Treatment with ImipenemEvaluation of Two Phenotypic Screening Tests for Carbapenemase-Producing EnterobacteriaceaeFluoroquinolone Resistance Mechanisms and population structure of Enterobacter cloacae non-susceptible to Ertapenem in North-Eastern France.Development of an algorithm for phenotypic screening of carbapenemase-producing Enterobacteriaceae in the routine laboratoryCosts associated with implementation of a strict policy for controlling spread of highly resistant microorganisms in France.In Vitro Susceptibility to Ceftazidime-Avibactam of Carbapenem-Nonsusceptible Enterobacteriaceae Isolates Collected during the INFORM Global Surveillance Study (2012 to 2014).Altered Outer Membrane Transcriptome Balance with AmpC Overexpression in Carbapenem-Resistant Enterobacter cloacaeIn-vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modification.Carbapenemase-producing Enterobacteriaceae in the UK: a national study (EuSCAPE-UK) on prevalence, incidence, laboratory detection methods and infection control measures.Carbapenemase-producing Escherichia coli is becoming more prevalent in Spain mainly because of the polyclonal dissemination of OXA-48.Molecular Characterization of Carbapenem-Nonsusceptible Enterobacterial Isolates Collected during a Prospective Interregional Survey in France and Susceptibility to the Novel Ceftazidime-Avibactam and Aztreonam-Avibactam Combinations.Prevalence and molecular characterization of carbapenemase-producing gram-negative bacteria from a university hospital in China.A new mechanism to render clinical isolates of Escherichia coli non-susceptible to imipenem: substitutions in the PBP2 penicillin-binding domain.Surveillance of antibiotic susceptibility of urinary tract pathogens for a population of 5.6 million over 4 years.Faecal carriage of carbapenemase-producing Gram-negative bacilli in hospital settings in southern France.OXA-48-like carbapenemases producing Enterobacteriaceae in different niches.Effect of faecal microbiota transplantation on mouse gut colonization with carbapenemase-producing Escherichia coli.OXA-48-producing ST372 Escherichia coli in a French dog.The tigecycline evaluation and surveillance trial; assessment of the activity of tigecycline and other selected antibiotics against gram-positive and gram-negative pathogens from France collected between 2004 and 2016.
P2860
Q26744583-3D0E0849-5C3C-48A9-BE31-496C1A59722CQ34298270-A66E7AD9-BC66-41CA-9DED-033988BC51A2Q34597608-53C1143F-0363-4419-833D-F6564C6B5175Q35607803-C8CAE37C-6D9B-4BA7-BB6C-5C7D54B38571Q35617499-F70348A7-E6D9-4E4F-9411-E977009B75FFQ35785140-86F7765C-3A20-4687-B94C-7574DD8500BEQ36066876-4B9BCF1A-4BFF-49B4-9A3E-C372D069BCCFQ36196200-C49639A6-C815-4EE5-91ED-42B34002BA91Q36251716-0F6624BE-AD2A-48EF-B02C-2E027C27C582Q36526872-14B6034E-96AC-428F-9B5E-F5F887D75B40Q36888062-398C7FF0-696A-4933-AF04-19CFA75C546CQ37528489-50B49F6C-3CAF-429A-B9AB-439A56E70392Q40116299-997FD2C6-E321-4510-8F37-1DABEF57DFB2Q40522152-AC5B330F-614A-48AC-81B6-5813F40AE68AQ40687135-0A635CAF-62F4-4722-B3CD-5EFDD5E7C823Q40945550-DB650531-C126-4B51-B269-F354A620C080Q40954459-E8FE0C5B-03F7-4607-BBEC-439B0BFFA0DBQ40954637-E06B61AD-2D47-4545-8DAF-D4D71C9093B3Q41315930-DEE591C5-4AE5-4C0B-B32A-19658935EBF6Q41586909-3BC505FF-5705-4979-9CB2-DBA8DF25D10CQ46291390-AF035CC7-7A2D-4074-B720-0994BC960836Q53746799-C0719468-975F-4DF2-9915-915EB4A76220Q54460175-1587D8A7-3075-46A2-ACB2-098D4419C32EQ55422215-38579740-8FAE-4ACD-B0E2-13761E8F2B35
P2860
Incidence rates of carbapenemase-producing Enterobacteriaceae clinical isolates in France: a prospective nationwide study in 2011-12.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@en
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@nl
type
label
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@en
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@nl
prefLabel
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@en
Incidence rates of carbapenema ...... e nationwide study in 2011-12.
@nl
P2093
P2860
P356
P1476
Incidence rates of carbapenema ...... ve nationwide study in 2011-12
@en
P2093
Alix Pantel
Audrey Mérens
Jean-Philippe Lavigne
Marie-Hélène Nicolas-Chanoine
ONERBA's Carbapenem Resistance Study Group
P2860
P304
P356
10.1093/JAC/DKU208
P407
P577
2014-06-16T00:00:00Z